The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
September 29, 2025
View Complete Issue         Table of Contents 2019 
Dordaviprone (Modeyso) for Diffuse Midline Glioma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dordaviprone (Modeyso) for Diffuse Midline Glioma (online only)
September 29, 2025 (Issue: 1738)
Dordaviprone (Modeyso – Jazz), an oral protease activator, has received accelerated approval from the FDA for treatment of diffuse midline gliomas harboring a H3 K27M mutation in patients ≥ year old who had disease progression following prior...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dordaviprone (Modeyso) for Diffuse Midline Glioma (online only)
Article code: 1738c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.